The firm is a life sciences-focused venture capital firm with a global presence and a track record of investing across private and public markets. The firm manages multiple funds backed by institutional and strategic investors and has built a diversified portfolio of companies, including a meaningful number of seed and incubated ventures. The investment team brings extensive experience across venture investing, biopharmaceutical development, academia, and regulatory environments. The firm operates globally with team members based across key innovation hubs in North America and Asia.  

The firm invests across the life sciences sector, targeting areas of high unmet medical need. The firm is flexible across geographies and development stages, leveraging a cross-functional platform to support value creation from early company formation through later-stage and public market investing.  

From a company and management team perspective, the firm prefers to lead investments and typically takes board representation. The firm plays an active role in supporting portfolio companies through strategic guidance across capital markets, business development, clinical strategy, regulatory planning, and commercialization. The firm seeks to partner with management teams that demonstrate strong capability, commitment, and the ability to advance innovative technologies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm funds and co-founds early-stage companies using AI to transform the future of healthcare. The firm invests in US-based techbio and healthtech companies at the Seed and Series A stages, more often at Seed. The typical check sizes range from $0.5M-3M and the firm reserves for follow-on rounds. 
 
The firm’s sectors of focus include biopharma tech and services, precision medicine, life sciences SaaS and tools, novel care delivery, and novel payment models. The firm does not invest in pure therapeutics or medical devices. 
 
The firm does not have strict management team requirements; however, they look for founders who are knowledgeable domain experts with a bold vision for how their company will make a lasting contribution to the advancement of an industry or solve a massive healthcare challenge. As leaders, they build high-functioning teams and earn trust quickly. The firm may take a board or observer seat on a case-by-case basis, but it is not a requirement. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a strategic family office-backed investment vehicle focused on advancing innovation in the life sciences sector, with a particular emphasis on AI-driven therapeutic development. The firm typically invests in Seed through Series A biotechnology companies, deploying capital in the low- to mid-single-digit millions. The firm maintains a balanced portfolio strategy, supporting both early-stage and select growth-stage opportunities to diversify risk and drive long-term value creation. While the firm evaluates opportunities nationally, it has a strong focus on supporting companies in the Midwest region.  

The firm focuses on AI-driven drug discovery, computational biology, bioinformatics, and precision medicine. The firm prioritizes companies with strong scientific validation, data-driven platforms, and scalable technologies capable of advancing innovation in the life sciences industry.  

From a company and management team perspective, the firm does not impose strict requirements and remains open to engaging with a wide range of teams and opportunities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a venture capital firm based in Western Europe, established in 2020, focused on enabling technologies within life sciences and healthcare. The firm invests from an early-stage fund and typically makes initial investments starting around €1M, with the capacity to deploy additional capital through follow-on rounds totaling several million euros per company. The firm invests across Seed to Series B stages and aims to be a meaningful investor, often leading or co-leading rounds while also participating in syndicates. The firm maintains a regional focus on Western Europe and has an active investment pace with multiple portfolio companies and exits to date.  

The firm focuses on diagnostics, medical devices, and digital health opportunities. The firm does not invest in therapeutics and avoids invasive devices, particularly higher-risk regulatory classifications. The firm evaluates companies with regulatory progress and early clinical validation, including those at or around initial clinical stages.  

From a company and management team perspective, the firm does not impose strict requirements but takes a hands-on approach to investing. The firm typically requires board representation and works closely with portfolio companies to support growth, development, and commercialization. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global healthtech and life sciences investment fund has a presence across North America and the Middle East. The firm manages significant assets and partners with entrepreneurs developing transformative science and technology to improve healthcare outcomes. The investment team is multidisciplinary, bringing together expertise across science, medicine, engineering, and venture investing, and actively supports portfolio companies through a platform-oriented approach.  

The firm invests across the full company lifecycle through multiple strategies. An early-stage strategy focuses on company creation, academic spinouts, and Seed to Series A investments in disruptive technologies. A complementary growth strategy targets later-stage companies in expansion rounds, pre-IPO financings, or pivotal clinical development. The firm supports companies from early innovation through commercialization and scaling.  

The firm invests broadly across therapeutics, medical devices, diagnostics, digital health, and life science tools. Key areas of interest include precision and personalized medicine, multi-omics, next-generation cell and gene therapies, engineered biology, and digital transformation of diagnostics and care delivery. For biotech and medtech, the firm is particularly interested in companies with early clinical proof of concept and near-term value inflection points. In diagnostics and tools, the firm targets breakthrough technologies approaching commercialization. In digital health, the firm focuses on companies with demonstrated revenue traction and scalability.  

From a company and management team perspective, the firm seeks strong, execution-oriented teams capable of solving complex problems and achieving product-market fit. The firm prioritizes opportunities addressing significant unmet medical needs with clear pathways to market access and long-term value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a globally diversified healthcare venture capital firm headquartered in Asia, with a strong presence across North America, Europe, and other international markets. The firm maintains a globally balanced portfolio and partners with a broad network of institutional, clinical, and commercial stakeholders. In addition to capital, the firm provides hands-on support in strategy, cross-border expansion, manufacturing partnerships, and distribution, helping portfolio companies scale internationally and navigate complex healthcare ecosystems.  

The firm invests across early- to growth-stage opportunities, with a focus on medical devices, digital health, healthcare services, and AI-enabled solutions. Key areas of interest include oncology and radiotherapy, ophthalmology, brain health and neuromodulation, cardiovascular diseases, women’s and children’s health, and chronic disease management such as diabetes. The firm prioritizes technologies that address meaningful clinical needs and have the potential for broad global impact.  

From a company and management team perspective, the firm seeks to partner with mission-driven founders developing innovative healthcare solutions. The firm does not impose strict requirements on management teams but values integrity, strong execution capability, and the ability to scale across international markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

 
The firm is a life sciences venture capital firm based in the United States focused on early- and growth-stage biotech and pharmaceutical companies. The firm manages substantial assets and typically makes initial investments in the low- to mid-single-digit millions, primarily through equity, with occasional use of convertible structures. The firm seeks to take meaningful ownership positions and plays an active role in the development of its portfolio companies. While the firm invests across the U.S., it has a particular interest in opportunities outside of the major biotech hubs.  

The firm focuses exclusively on therapeutic companies within the biotechnology sector. The firm is generally agnostic to modality and indication but prioritizes assets with novel mechanisms of action that address clear unmet medical needs. The firm typically invests in companies ranging from late preclinical through Phase II clinical development. The firm does not invest in diagnostics, medical devices, digital health, or healthcare IT.  

From a company and management team perspective, the firm does not impose strict requirements but typically requires board representation in connection with its investments to enable active collaboration and strategic involvement throughout company development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.